Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common-Size Income Statement

Beginner level

Regeneron Pharmaceuticals Inc., common-size consolidated income statement

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Net product sales 65.52 61.48 61.19 63.32 68.69
Sanofi collaboration revenue 13.96 18.14 16.56 14.94 13.55
Bayer collaboration revenue 13.96 15.12 16.04 15.97 15.31
Other revenue 6.56 5.26 6.21 5.76 2.45
Revenues 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of goods sold -5.79 -4.61 -2.68 -3.45 -4.00
Cost of collaboration and contract manufacturing -7.39 -5.34 -3.79 -3.31 -2.16
Cost of revenues -13.18% -9.95% -6.47% -6.76% -6.17%
Gross profit 86.82% 90.05% 93.53% 93.24% 93.83%
Research and development -32.19 -38.62 -32.58 -35.34 -42.22
Selling, general, and administrative -15.84 -23.33 -23.19 -22.49 -24.23
Other operating income (expense), net 3.30 0.00 0.00 0.00 0.00
Income from operations 42.09% 28.10% 37.77% 35.41% 27.38%
Other income (expense), net 3.42 3.17 0.70 0.41 0.13
Interest expense -0.67 -0.38 -0.42 -0.43 -0.15
Other income (expense) 2.75% 2.79% 0.28% -0.02% -0.02%
Income before income taxes 44.84% 30.89% 38.05% 35.40% 27.36%
Income tax expense -3.50 -3.98 -1.63 -14.99 -8.94
Net income 41.35% 26.91% 36.42% 20.41% 18.42%

Based on: 10-K (filing date: 2021-02-08), 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Regeneron Pharmaceuticals Inc.’s income from operations as a percentage of revenues decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Regeneron Pharmaceuticals Inc.’s income before income taxes as a percentage of revenues decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc.’s net income as a percentage of revenues decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level.